GTC
Global Technology Community

EUROPEAN PHARMA SUMMIT

Includes the four co-located conferences:

10th Drug Design & Medicinal Chemistry

3rd 3D Models & Drug Screening

2nd Kinase Inhibitors Design & Screening

3rd GPCR Targeted Screening

MAY 11-13, 2016 • BERLIN, GERMANY

Platinum Sponsor

CHEMICAL COMPUTING GROUP

Gold Sponsors

REACTION BIOLOGY CORP.

TEMPER technologies

Visit **www.gtcbio.com** for more information!

ABOUT

We invite you to attend the **European Pharma Summit 2016**, which will take place on **May 11-13, 2016** in **Berlin, Germany**. This event seeks to create a forum for colleagues across multiple disciplines, as well as from both private and public sectors, to gather and exchange ideas. Delegates from pharmaceutical organizations, biotech companies, and leading academic institutions will gather over the course of four days to listen to presentations on the hottest topics in drug discovery and network with both new and old colleagues.

The landscape for drug discovery has changed drastically over the past few years: private and public partnerships are changing how research is being done, researchers are using 3D model systems in hopes of improving clinical outcomes, and emerging target classes are changing traditional conceptions of the drug discovery process.

The Summit will feature four conferences that will cover the latest hot topics in drug discovery:

10th Drug Design & Medicinal Chemistry *(May 11-12)*

3rd 3D Models & Drug Screening *(May 11-12)*

3rd GPCR Targeted Screening *(May 12-13)*

2nd Kinase Inhibitors Design & Screening *(May 12-13)*

POSTER & ORAL PRESENTATION OPPORTUNITIES

If you are interested in participating in the Summit's poster session to showcase your work and research, please submit an abstract here and select which conference you would like to present in by **April 11, 2016**. In addition, the top two to three abstracts submitted for each individual conference will be selected to give a short oral presentation as part of that conference's program. Presentation slots fill up fast so please submit your abstract ASAP.

2015 DEMOGRAPHICS





SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind: we create intimate and highly interactive environments so that they can maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

• Sponsors/exhibitors have the option to receive the delegate list a week before and a week after the conference.

• The exhibit space for the meeting is shared with any other concurrent conferences, providing sponsors and exhibitors with access to a larger audience. The exhibit space is also where all networking functions take place, including coffee, snack stations, breakfast, and the evening reception.

• Your corporate logo will be placed on the cover page of the conference brochures, the proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Nicolas Rodriguez
Account Executive
nicolas.rodriguez@gtcbio.com

SPONSORS

PLATINUM

CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG provides state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG headquarters are in Montreal (Canada), with support offices in North America, Europe and Asia.

GOLD

NanoTemper Technologies stands for a strong commitment to quality and high-precision instrumentation made in Germany. The extremely experienced and globally operating team of experts focuses strongly on users' benefits by ensuring maximum efficiency for research in pharmaceutical and biotechnology industries, as well as in academic research settings. This high-tech company develops, produces and markets technologies and instruments for biomolecular analytics, from basic to preclinical research. With headquarters in Munich, Germany, and subsidiaries in the UK, Poland, US, Brazil and India, the company is rapidly expanding worldwide. Among others, NanoTemper has been awarded the German Innovation Award 2012, the Bavarian Export Prize 2013 and the German Founders' Prize 2014. NanoTemper's high-quality instruments are based on proprietary and innovative technologies.

Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC's radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.

MEDIA PARTNERS

AGENDA AT-A-GLANCE

Day 1 - Wednesday, May 11, 2016

7:00	*Registration & Continental Breakfast*	
7:55	*Welcome & Opening Remarks*	
	10th Drug Design & Medicinal Chemistry	3rd 3D Models & Drug Screening
8:00	Session I: Targeting Protein-Protein Interactions	Session I: Engineering Relevant 3D Models for Target Identification & Drug Development
10:00	*Morning Networking Break*	
10:30	Session II: Chemogenomics and Chemical Biology for Target Identification and Validation	Session I: Engineering Relevant 3D Models for Target Identification & Drug Development (cont.)
12:40	*Lunch on Your Own*	
14:10	Session III: Novel Computational Methods	Session II: Microfluidics & Maximizing Physiological Relevance in 3D Models
16:15	*Afternoon Networking Break*	
16:45	Session IV: Immmuno-oncology & Therapeutic Potential Session V: Neuroprotective Drugs for the CNS & Blood Brain Barrier	Session III: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation
19:00	*Evening Reception & Poster Session*	

Day 2 - Thursday, May 12, 2016

7:00	*Registration & Continental Breakfast*		
7:55	*Welcome & Opening Remarks*		
	10th Drug Design & Medicinal Chemistry	2nd Kinase Inhibitors Design & Screening	3rd 3D Models & Drug Screening
8:00	Joint Session: Kinase Inhibitor Design & Overcoming Resistance and Selectivity		Session IV: Advances in the Functional Analysis of 3D Models
10:05	*Morning Networking Break*		
10:35	Joint Session: Kinase Inhibitor Design & Overcoming Resistance and Selectivity (cont.)		Session V: Translational Applications & Predictability of 3D Models
12:15	*Lunch Provided by GTCbio* *10th Drug Design & Medicinal Chemistry & 3rd 3D Models & Drug Screening Conclude* *Registration for 3rd GPCR Targeted Screening*		
	2nd Kinase Inhibitors Design & Screening		3rd GPCR Targeted Screening
13:45	Session II: Novel Tools & Technological Advances in Kinase Inhibitor Development		Session I: GPCR Chemical Biology & Novel Molecular Probes
15:25	*Afternoon Networking Break*		
15:55	Session III: Target Identification & Validation		Session II: Allosteric Modulators & Biased Signaling
18:00	*Evening Reception & Poster Session*		

All times are approximate and subject to changes without notice

AGENDA AT-A-GLANCE

Day 3 - Friday, May 13, 2016

	2nd Kinase Inhibitors Design & Screening	3rd GPCR Targeted Screening
7:00	*Continental Breakfast*	
8:00	Session IV: Biomarkers in Kinase Drug Discovery	Session III: GPCR Signaling Pathways and Mechanisms
9:40	*Morning Networking Break*	
10:10	Session V: Kinase Inhibitors for CNS Indications	Session III: GPCR Signaling Pathways and Mechanisms (cont.)
12:00	*Conference Concludes*	*Lunch Provided by GTCbio*
13:00		Session IV: GPCR Structure and Dynamics Session V: GPCRs in Disease
17:00		*Conference Concludes*

All times are approximate and subject to changes without notice

KEYNOTE SPEAKERS

Structure-Based Drug Design to Perturb Function of a tRNA-Modifying Enzyme by Active Site and Protein-Protein Interface Inhibition

Gerhard Klebe
University of Marburg

Design Strategies for the Development of Selective Kinase Inhibitors

Stefan Knapp
University of Oxford

Natural Products Revisited

Gisbert Schneider
ETH Zurich

DISTINGUISHED SPEAKERS

TNF-Alpha as Key Promoter of Breast Cancer Pathogenesis

Adit Ben-Baruch
Tel Aviv University

Designing Chemical Tools to Modulate Protein-Protein Interactions

John Karanicolas
University of Kansas

Integrating Halogen Bonds into Drug Discovery: Tools and Applications

Frank Boeckler
Eberhard Karls University, Tübingen

Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3-selective Probes

Stefan Laufer
University of Tübingen

MOEsaic: Making SAR Analysis Easier Through the Use of Matched Molecular Pairs

Gianpaolo Bravi
Chemical Computing Group

Structure-Based Design of Long Residence Time into Novel Kinase Inhibitors

Gerhard Mueller
Mercachem BV

Structure-Based Drug Design with G Protein-Coupled Receptors: The Discovery of Highly Selective M1 Agonists

Giles Brown
Heptares Therapeutics

Predictive Modeling Workflows Support Decision Making in Drug Design

Ingo Mugge
Boehringer-Ingelheim

One-click Drug Discovery Solutions among a Billion Compound Library

Carlos Camacho
University of Pittsburgh

Compound Biological Signatures for Target Identification and Library Design

Paula Petrone
Roche

DISTINGUISHED SPEAKERS

Towards the Validation of ULK1 as an Autophagy Target for Cancer

Nicholas Cosford
Sanford Burnham Prebys Medical Discovery Institute

From Models to Molecules: Using Zebrafish to Understand and Treat Epilepsy

Camila Esguerra
University of Oslo

Inhibiting Kinase Activity by Controlling Conformational Activation: Switch Control Inhibition

Daniel Flynn
Deciphera Pharmaceuticals

Prediction of Selectivity Determining Features in the ATP Binding Site of Kinases

Simone Fulle
BioMed X Innovation Center

Strategies and Outcomes for Fragments for Kinases

Roderick Hubbard
Vernalis
University of York

Session: Neuroprotective Drugs for the CNS & Blood Brain Barrier

ATLASVENTURE

Edward Holson
Atlas Venture

New Prototypes of AGC Kinase Inhibitors

Oliver Plettenburg
Sanofi-Aventis

Drug Discovery Targeting Protein-Protein Interactions: The 2P2I Approach

Philippe Roche
Cancer Research Centre of Marseille

Development of Small Molecules for Heart Regeneration

Dennis Schade
Technical University of Dortmund

Exploring Macrocycles for Protein-Protein Interaction Targets: The Discovery of Novel Oncology Drugs

Nicholas Terrett
Ensemble Therapeutics

Discovery of a Selective and Efficacious Syk Inhibitors

Gebhard Thoma
Novartis

Docking of Modeled Proteins and Conformational Properties of Their Interfaces

Ilya Vakser
University of Kansas

DISTINGUISHED SPEAKERS

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Natasa Anastasov
Helmholtz Institute Munich, Institute of Radiation Biology

Session: Advances in the Functional Analysis of 3D Models

Karsten Boehnke
Eli Lilly and Company

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Laure Bouchez
Novartis

Session: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation

Eugenio Fava
Deutsches Zentrum für Neurodegenerative Erkrankungen

Session: Translational Applications & Predictability of 3D Models

Darren Finlay
Sanford-Burnham-Prebys Medical Discovery Institute

Session: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation

Xavier Gidol
BIOMICS-INSERM U1038 (CEA/INSERM/ UGA)

Session: Translational Applications & Predictability of 3D Models

Eric Gottwald
Karlsruher Institut für Technologie

Session: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation

Andreas Muhlemann
Actelion Pharmaceuticals

Session: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation

David Nolte
Purdue University

Session: Microfluidics & Maximizing Physiological Relevance in 3D Models

Nathalie Picollet-D'hahan
BIOMICS- LBGE/INSERM

Session: Microfluidics & Maximizing Physiological Relevance in 3D Models

Qasim Rafiq
Aston University

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Markus Rimann
Zurich University of Applied Sciences, ICBT, Campus Reidbach

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Christian Scheems
NMI Natural and Medical Sciences Institute at the University of Tübingen

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Christopher Schofield
GlaxoSmithKline

DISTINGUISHED SPEAKERS (cont.)

Session: Translational Applications & Predictability of 3D Models

Dusko Ilic
King's College London

Novel Hepatic 3D Models for Drug Target Validation and Liver Disease

Magnus Ingelman-Sundberg
Karolinska Institute

Engineered Culture System for Enrichment of Cancer Stem Cells

Esmaiel Jabbari
University of South Carolina

Session: Translational Applications & Predictability of 3D Models

Beatrice Knudsen
Cedars Sinai Medical Center

Session: Microfluidics & Maximizing Physiological Relevance in 3D Models

Darren Tomlinson
University of Leeds

Session: Novel Tools & Imaging Technologies for High Content Phenotypic Screening and Validation

Francisca Vicente
Fundación MEDINA

Session: Engineering Relevant 3D Models for Target Identification & Drug Development

Wolfram-Hubertus Zimmermann
University Medical Center Goettingen

DISTINGUISHED SPEAKERS

Universal Allosteric Mechanism for Gα Activation by GPCRs

Madan Babu
MRC Lab of Molecular Biology

Voltage Dependence of GPCRs: Mechanisms and Dynamics

Moritz Bunemann
University of Marburg

Session: GPCR Signaling Pathways and Mechanisms

Peter Chidiac
Western University

Session: GPCR Structure and Dynamics

Robert Cooke
Heptares

Session: GPCRs in Disease

Olivier Corminboeuf
Actelion

Session: GPCR Signaling Pathways and Mechanisms

Andre-Leroux Gwenaelle
INRA (French National Institute for Agricultural Research) at Jouy en Josas

Session: GPCR Structure and Dynamics

Christopher Klenk
University of Zurich



Session: GPCR Signaling Pathways and Mechanisms

Karen O'Malley
Washington University School of Medicine

Session: GPCRs in Disease

Stefan Offermanns
Max-Planck-Institute for Heart and Lung Research



Session: GPCR Structure and Dynamics

Xianhua Piao
Harvard Medical School & Boston Children's Hospital

Session: Allosteric Modulators & Biased Signaling

Patricia Reggio
University of North Carolina

Session: GPCR Signaling Pathways and Mechanisms

Philippe Rondard
French National Institute of Health and Medical Research (Inserm)

Characterization of Novel Pharmacological Tools for Neuropeptide FF Receptors

Frederic Simonin
ESBS Université de Strasbourg

Session: GPCRs in Disease

Martine Smit
Vrije Universiteit, Amsterdam

DISTINGUISHED SPEAKERS

The Role of CCR5 Conformational Heterogeneity in the Development of HIV Infection and the Potency of Antiviral Strategies

Bernard Lagane
Institut Pasteur Paris

Regulation of 5-HT6 Receptor Constitutive Activity by Interacting Partners

Philippe Marin
Institut de Génomique Fonctionnelle

Tissue-Specific Delivery of Thyroid Hormone Reverses Diet-Induced Obesity, Dyslipidemia and Steatosis in Mice

Timo Muller
Helmholtz Zentrum Munchen



Session: GPCR Signaling Pathways and Mechanisms

Jan Steyaert
Vrije Universiteit Brussel

Session: Allosteric Modulators & Biased Signaling

Franck Vandermoere
IGF Université de Montpellier, CNRS



Session: GPCR Signaling Pathways and Mechanisms

Kevin Xiao
Duke University Medical Center

KEYNOTE SPEAKER

Design Strategies for the Development of Selective Kinase Inhibitors

Stefan Knapp
University of Oxford

DISTINGUISHED SPEAKERS

AGC Kinases: From Molecular Mechanism of Regulation to Allosteric Drug Development

Ricardo Biondi
University of Frankfurt

DYRK1A Inhibitors as Potential Therapeutic Drugs fro Down Syndrome and Alzheimer's Disease

Laurent Meijer
ManRos Therapeutics

Selective TTK Inhibitors with Long Target Residence Time and Potent Anti-Tumor Activity

Rogier Buijsman
Netherlands Translational Research Center

Structure-Based Design of Long Residence Time into Novel Kinase Inhibitors

Gerhard Mueller
Mercachem BV

Addressing the Inflammatory Aspects of Amyloidosis using CNS Penetrant p38 Kinase Inhibitors

Michael Burnet
Synovo

The Allosteric Backpocket - A General Concept for Kinase Inhibition?

Henrik Moebitz
Novartis



Opportunities and Liabilities Associated with Targeting the PKC and PKN Kinases

Angus Cameron
Barts Cancer Institute

Development of Selective IRAK4 Inhibitors for Target Validation

Xiaoda Niu
Merck Research Laboratories

Patient-Specific Kinase Targets in Cancer

Pedro Cutillas
Barts Cancer Institute

Discovery of Potent, Selective, and Brain Penetrant Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)

Snahel Patel
Genentech

PI3K Inhibition and Microtubule Binding

Doriano Fabbro
PIQUR Therapeutics

New Prototypes of AGC Kinase Inhibitors

Oliver Plettenburg
Sanofi-Aventis

DISTINGUISHED SPEAKERS

Inhibiting Kinase Activity by Controlling Conformational Activation: Switch Control Inhibition

Daniel Flynn
Deciphera Pharmaceuticals

Strategies and Outcomes for Fragments for Kinases

Roderick Hubbard
University of York
Vernalis

Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3-selective Probes

Stefan Laufer
University of Tübingen

Session: Novel Tools & Technological Advances in Kinase Inhibitor Development

David Litchfield
Western University

Session: Target Identification & Validation

Soumya Ray
Schrodinger

Discovery of a Selective and Efficacious Syk Inhibitors

Gebhard Thoma
Novartis

Second-Harmonic Generation (SHG) as a Sensitive, Real-Time Probe of Protein Conformation

Joshua Salafsky
Biodesy

Extending Kinome Coverage by Analysis of Kinase Inhibitor Broad Profiling Data

Herman van Vlijmen
Janssen

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:
20% until March 11, 2016
10% until April 11, 2016

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**

To register online, visit: www.gtcbio.com/register/european-pharma-summit

	Commercial	Academic / Govt	Student
Summit	2750.00	1450.00	1050.00
2 day pass - 2 conferences	2150.00	1150.00	950.00
Individual Conference	1950.00	975.00	775.00

QUICK REGISTRATION - FAX TO (626) 466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

Maritim Hotel Berlin
Stauffenbergstrasse 26
10785 Berlin
+49 (0) 30 2065-0

Discounted Group Rate: Single 129€ per night
Discount Deadline: April 11, 2016
Mention ***GTCbio*** to receive the group rate.

Online Reservations: click here or
send an email to reservierung.ber@maritim.de



PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form here.
Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.